MINIMALLY INVASIVE WEIGHT LOSS (BARIATRIC) DEVICES | GLOBAL MARKETS

184 Pages | 54 Exhibits | 2017 Analysis | Forecasts Through 2021 Product Family: Market Reports




OVERVIEW:
This analysis includes a discussion of medical devices, market forecasts, competitors, and opportunities in the global minimally invasive weight loss (bariatric) devices market. This market focuses on 3 core segments: 1) laparoscopic adjustable gastric banding systems 2) intragastric balloons, and 3) implantable neuroregulators/gastric stimulators, as well as emerging technologies.

MINIMALLY INVASIVE WEIGHT LOSS MARKET HIGHLIGHTS

  • The minimally invasive weight loss devices market was valued at more than $137m in 2016 and is expected to grow at a double-digit rate over the next 5 years.
  • The most promising segment is intragastric balloon systems, an area exhibiting significant growth potential and innovation.
  • The US accounted for more than 1/3 of the total market in 2016 and is expected to experience growth approaching a 15% CAGR, however, selected markets OUS will also expand due to rising global rates of obesity.
  • The overall market will be driven by highly favorable demographics, low penetration, strong demand for safe and effective nonsurgical weight loss therapies (filling an underserved market between weight loss drugs and drastic bariatric surgery), and increased adoption of next-generation, implantable weight loss technologies
Key Questions Answered
  • What is the value of the minimally invasive weight loss devices market? What is the expected growth over the next 5 years? Which segments are leading, and which are lagging?
  • What is the expected market growth by major geographical region (US, 5EU, and RoW)?
  • What are the key market drivers & limiters? Major trends driving growth?
  • Who are the leading competitors and their market share by region, and strategies for market growth?
  • Which technologies developed by innovative start-ups are expected to impact the market?


TABLE OF CONTENTS:
EXECUTIVE SUMMARY 

i. Report overview 
ii. Obesity overview and prevalence 
iii. Minimally invasive weight loss devices market 
	a. Selected market drivers and limiters 
	b. Laparoscopic adjustable gastric banding devices segment 
	c. Intragastric balloon systems segment 
	d. Implantable neuroregulators/gastric stimulation systems segment 
	e. Technology trends 
	f. Market leaders 
	g. Competitive strategies 
	h. Emerging competition/startups 
iv. Methodology 

Exhibit ES-1: Minimally invasive weight loss devices market forecast, by segment ($m), 2016-21 
Exhibit ES-2: Minimally invasive weight loss devices market, estimated share by region, 2016 and 2021 

1. OVERVIEW OF OBESITY
 
1.1 Classification of overweight and obesity 
1.2 Co-morbidities 
	1.2.1 Diabetes and obesity 
1.3 Obesity prevalence 
	1.3.1 Worldwide prevalence 
	1.3.2 US prevalence 
	1.3.3 Obesity forecast for the US, Japan, and five major EU markets 
	1.3.4 Obese adults with diabetes forecast (the US and five major EU markets) 
	1.3.5 Obesity forecasts for Brazil and China 
		1.3.5.1 Brazil 
		1.3.5.2 China 
1.4 Causes 
1.5 Bariatric surgery 
	1.5.1 Risks and benefits 
	1.5.2 Physicians recommend bariatric surgery over obesity drugs 
	1.5.3 Costs of obesity and bariatric surgery 
	1.5.4 Gastric bypass 
	1.5.5 Sleeve gastrectomy 
1.6 Minimally invasive weight loss alternatives 
	1.6.1 Laparoscopic adjustable gastric banding 
	1.6.2 Non-surgical intragastric balloon systems 
	1.6.3 Implantable vagal blocking/gastric stimulation devices 
	1.6.4 Emerging minimally or non-invasive options 
1.7 Bibliography 

Exhibit 1-1: Obesity prevalence across the US, Japan, and five major EU markets, all ages, by country, 2016-21 
Exhibit 1-2: Segmentation of prevalent adult obesity cases in the US, Japan, and five major EU markets, by class and country (%), 2016 
Exhibit 1-3: Diabetes prevalence in adult obese patients across the US and five major EU markets, by country, 2016-21 
Exhibit 1-4: Overweight and obesity prevalence across Brazil and China, all ages, 2016-21 
Exhibit 1-5: Obesity prevalence across the US, Japan, five major EU markets, Brazil, and China, all ages, by country, 2016-21 

2. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING SYSTEMS
 
2.1 Leading LAGB systems 
	2.1.1 Apollo Endosurgery 
		2.1.1.1 Additional clinical data 
			2.1.1.1.1 Band erosion and high failure rate 
		2.1.1.2 Cost and reimbursement 
	2.1.2 Ethicon/Johnson & Johnson 
	2.1.3 Other LAGB systems (available outside the US) 
		2.1.3.1 Agency for Medical Innovations 
		2.1.3.2 Cousin Biotech 
		2.1.3.3 Helioscopie 
		2.1.3.4 Medical Innovation Developpement 
2.2 Bibliography 

Exhibit 2-1: Laparoscopic adjustable gastric banding systems, 2017 
Exhibit 2-2: Apollo Endosurgery's LAP-BAND 
Exhibit 2-3: Key benefits and risks/disadvantages of the LAP-BAND procedure 
Exhibit 2-4: Comparison of gastric banding, gastric bypass, and sleeve gastrectomy 
Exhibit 2-5: Agency for Medical Innovations' Soft Gastric Band Premium 
Exhibit 2-6: Cousin Biotech's Bioring adjustable gastric band 
Exhibit 2-7: Helioscopie's Heliogast HAGA adjustable gastric band 
Exhibit 2-8: Medical Innovation Developpement's MIDBAND adjustable gastric band 

3. INTRAGASTRIC BALLOON SYSTEMS 

3.1 Safety and efficacy 
	3.1.1 FDA warning 
3.2 Allurion Technologies 
3.3 Apollo Endosurgery 
3.4 Helioscopie 
3.5 Obalon Therapeutics 
3.6 ReShape Medical 
3.7 Spatz FGIA 
3.8 Bibliography 

Exhibit 3-1: Key benefits and risks/disadvantages of intragastric balloon systems 
Exhibit 3-2: Intragastric balloon systems, 2017 
Exhibit 3-3: Allurion Technologies' Elipse capsule-based, naturally excreted intragastric balloon 
Exhibit 3-4: Apollo Endosurgery's Orbera gastric balloon 
Exhibit 3-5: Orbera pivotal US trial results 
Exhibit 3-6: Helioscopie's Heliosphere intragastric balloon 
Exhibit 3-7: The Obalon capsule-based three-balloon system 
Exhibit 3-8: ReShape Integrated Dual Balloon System 
Exhibit 3-9: REDUCE pivotal trial results 
Exhibit 3-10: The Spatz3 Adjustable Balloon System 
Exhibit 3-11: The Spatz Adjustable Balloon procedure 

4. IMPLANTABLE VAGAL BLOCKING THERAPY
 
4.1 EnteroMedics 
	4.1.1 Device components and mechanism of action 
	4.1.2 Clinical trial results 
	4.1.3 Reimbursement issues 
4.2 MetaCure 
4.3 Bibliography 

Exhibit 4-1: Implantable electrical stimulators/neuroregulators for the treatment of obesity, 2017 
Exhibit 4-2: EnteroMedics' implantable vBloc Maestro Rechargeable System 
Exhibit 4-3: Overview of EnteroMedics' vBloc therapy and vagus nerve function 
Exhibit 4-4: Potential benefits and risks of vBloc therapy 
Exhibit 4-5: Comparison of vBloc therapy, laparoscopic banding, and gastric bypass, and complication rates 
Exhibit 4-6: MetaCure's DIAMOND II gastric stimulation system 

5. EMERGING MINIMALLY INVASIVE WEIGHT LOSS DEVICES
 
5.1 Aspire Bariatrics 
5.2 BarioSurg/EnteroMedics 
5.3 BAROnova 
5.4 GI Dynamics 
5.5 GI Windows 
5.6 Scientific Intake 
5.7 Bibliography 

Exhibit 5-1: Selected new minimally invasive device technologies for the treatment of obesity, 2017 
Exhibit 5-2: Aspire Bariatric's AspireAssist 
Exhibit 5-3: BarioSurg/EnteroMedics' Gastric Vest System 
Exhibit 5-4: BAROnova's TransPyloric Shuttle 
Exhibit 5-5: GI Dynamic's EndoBarrier Gastrointestinal Liner system and procedure 
Exhibit 5-6: GI Windows' incisionless anastomosis system procedure 
Exhibit 5-7: Scientific Intake's SmartByte Device 

6. MINIMALLY INVASIVE WEIGHT LOSS DEVICES MARKET
 
6.1 Global market analysis 
	6.1.1 Market forecast 2016-21 
	6.1.2 Market forecast by region 
		6.1.2.1 Market forecast: US 
		6.1.2.2 Market forecast: five major EU markets 
		6.1.2.3 Market forecast: rest of the world 
	6.1.3 Market forecast by product 
	6.1.4 Market forecast exhibits 
	6.1.5 Competitive analysis: laparoscopic adjustable gastric banding systems 
		6.1.5.1 Global market share (total market) 
		6.1.5.2 US market share 
		6.1.5.3 Five major EU markets share 
		6.1.5.4 RoW market share 
	6.1.6 Competitive analysis: intragastric balloon systems 
		6.1.6.1 Global market share (total market) 
		6.1.6.2 US market share 
		6.1.6.3 Five major EU markets share 
		6.1.6.4 RoW market share 
	6.1.7 Competitive analysis: implantable neuroregulators (vagal blocking) and gastric stimulation systems 
		6.1.7.1 Global market share (total market) 
	6.1.8 Detailed analysis, by competitor 
		6.1.8.1 Apollo Endosurgery 
			6.1.8.1.1 Strategic growth initiatives 
		6.1.8.2 EnteroMedics 
			6.1.8.2.1 Strategic growth initiatives 
		6.1.8.3 Obalon Therapeutics 
			6.1.8.3.1 Strategic growth initiatives 
6.2 Bibliography 

Exhibit 6-1: Minimally invasive weight loss devices market forecast, by segment and region, 2016-21 
Exhibit 6-2: Minimally invasive weight loss devices market, estimated share by region, 2016 and 2021
Exhibit 6-3: Minimally invasive weight loss devices market, estimated share by device segment, 2016 and 2021 
Exhibit 6-4: Laparoscopic adjustable gastric banding systems market, comparison of share by supplier (%), by region, 2016 
Exhibit 6-5: Laparoscopic adjustable gastric banding systems global market, share by supplier, 2016 
Exhibit 6-6: Laparoscopic adjustable gastric banding systems US market, share by supplier, 2016 
Exhibit 6-7: Laparoscopic adjustable gastric banding systems five major EU markets, share by supplier, 2016 
Exhibit 6-8: Laparoscopic adjustable gastric banding systems RoW market, share by supplier, 2016 
Exhibit 6-9: Intragastric balloon systems market, comparison of share by supplier (%), by region, 2016 
Exhibit 6-10: Intragastric balloon systems global market, share by supplier, 2016 
Exhibit 6-11: Intragastric balloon systems US market, share by supplier, 2016 
Exhibit 6-12: Intragastric balloon systems five major EU markets, share by supplier, 2016 
Exhibit 6-13: Intragastric balloon systems RoW market, share by supplier, 2016 
Exhibit 6-14: Implantable neuroregulators/gastric stimulation systems market, comparison of share by supplier (%), by region, 2016 
Exhibit 6-15: Implantable neuroregulator/gastric stimulation systems global market, share by supplier, 2016 

APPENDIX A: COMPANY LISTING


COMPANIES COVERED:

  1. Agency for Medical Innovations (A.M.I.)
  2. Allium Medical
  3. Allurion Technologies
  4. Apollo Endosurgery, Inc.
  5. Aspire Bariatrics, Inc.
  6. BarioSurg, Inc.
  7. BAROnova, Inc.
  8. Cousin Biotech
  9. EnteroMedics
  10. Ethicon
  11. Gelesis
  12. GI Dynamics, Inc.
  13. GI Windows, Inc.
  14. Helioscopie
  15. Medical Innovation Developpement
  16. MetaCure
  17. Obalon Therapeutics, Inc.
  18. ReShape Medical, Inc.
  19. Scientific Intake Limited Co.
  20. Spatz FGIA, Inc.
Contact Us

Need help finding medtech research? Let us help you!